A remarkable interplay has also been described between PRMT5 and the B cell lymphoma 6 (BCL6) oncogene during the lymphomagenesis in the GC (Lu et al., 2018), suggesting that pharmacological inhibition of arginine methylation could be of special interest in BCL6-driven lymphoma. The gene discussed is BCL6; the disease is lymphoma.